riboxx pharmaceuticals has developed four families of TLR3 & RLR agonists for immunotherapy of cancer or immunotherapy of virus diseases.
Immunotherapy of cancer
- RIBOXXIM® is a TLR3 ligand for ex vivo immunotherapy of cancer, therapeutic vaccination against cancer, and prevention of cancer recurrence.
- APOXXIM® is a TLR3 ligand for first-line immunotherapy of cancer.
- RIBOXXON® is a TLR3-bioconjugate for targeted immunotherapy of cancer.
Immunotherapy of virus diseases
- RIBOXXOL® is a TLR3 ligand for therapeutic vaccination against virus diseases, i.e. Hepatitis B virus.
RIBOXXIM, APOXXIM, RIBOXXON and RIBOXXOL have unique properties as to biological activity, analytical purity, pharmakokinetics, and toxicity profile.
Mechanism of action
The drug products developed at riboxx pharmaceuticals act by activating the so called "innate immune system".
The innate immune system is the first line of defense of the body. It is also the oldest immune defense strategy, and is found in all classes of animal life. It is a non-specific immune system, (i.e. not specific for one pathogen), being triggered by molecular patterns, such as double-stranded RNA (dsRNA).
Immune cells playing an important role in innate immunity include dendritic cells, macrophages, neutrophils, and Natural Killer cells. These cells are directly implicated in mounting a potent immune response to cancer or virus infections.
The drug products of riboxx pharmaceuticals belong to the class of Toll-like-Receptor 3 agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The drug substance is RNA (ribonucleic acid).